Puma Biotechnology Q3 2026: EPS beat masks a China royalty hit

As seen on the 24/7 Wall St. homepage on November 5, 2026.

PBYI Puma Biotechnology
Q3 2026
EPS
$0.15
est $0.12 +25.0%
Revenue
$55M
est $58M -4.2%

Generic NERLYNX crossed a market-share threshold in China, forcing a $2.1 million royalty writedown that pushed revenue below expectations even as earnings cleared consensus. Management raised full-year net income guidance to $20 million to $22 million and says delayed ex-US partner shipments land in the fourth quarter.

Continue ReadingShow less

Puma Biotechnology reported non-GAAP adjusted EPS of $0.15 for the third quarter of 2026, beating the $0.12 consensus estimate. Revenue of $55.1 million came in below the $57.5 million consensus, missing expectations.

The single biggest drag was a $2.1 million reduction to royalty revenue, booked as a change in accounting estimate after new data confirmed that generic NERLYNX had crossed a specified market-share threshold in China. That adjustment pulled royalty revenue down to $1.0 million for the quarter, compared with $2.6 million in the year-ago period, and was the primary reason total revenue barely moved year over year despite improved U.S. demand for NERLYNX.

On the product side, U.S. NERLYNX sales faced a headwind from a higher-than-expected gross-to-net deduction driven by an increase in Medicaid and 340B sales. A batch of ex-U.S. partner shipments also slipped out of the quarter entirely, shifting into Q4, which further capped reported revenue without reflecting any underlying demand weakness.

Sponsored

Despite the top-line shortfall, management raised its full-year net income guidance to $20 million to $22 million, up from the prior range of $17 million to $20 million. The deferred partner shipments are expected to lift Q4 total revenue to $67 million to $70 million, providing a concrete catalyst to watch when fourth-quarter results are reported.

On the pipeline front, Puma initiated ALISCA-Lung2 in September 2026, a Phase II trial evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer. Enrollment also continues in ALISCA-Breast1 and ALISCA-Lung1, and updated ALISCA-Breast1 data is expected to be presented at the San Antonio Breast Cancer Symposium in December 2026, the next meaningful readout for investors tracking the alisertib program.

Mentioned: PBYI